Table 3.
Drug susceptibility prediction: single classes and combinations differentiated by B subtype and Non-B subtype population from 2017 to 2019 and 2020 to 2024.
| NRTI n (%) |
NNRTI n (%) |
PI n (%) |
N + NNRTI n (%) |
NRTI + PI n (%) |
NNRTI + PI n (%) |
Three Drug Classes n (%) |
Total n (%) |
|
|---|---|---|---|---|---|---|---|---|
| B Subtype | ||||||||
| 2017–2019 | 7 (3.0%) |
25 (11.0%) * |
1 (0.4%) |
2 (0.9%) |
0 | 0 | 0 | 35/227 (15.41%) * |
| 2020–2024 | 4 (2.4%) |
17 (10.2%) * |
1 (0.6%) |
0 | 0 | 1 (0.6%) |
1 (0.6%) |
24/167 (14.3%) * |
| Non-B Subtype | ||||||||
| 2017–2019 | 1 (0.5%) |
20 (10.7%) * |
1 (0.5%) |
0 | 0 | 0 | 0 | 22/187 (11.7%) * |
| 2020–2024 | 2 (1.1%) |
28 (15.5%) * |
1 (1.1%) |
3 (1.7%) |
0 | 1 (1.1%) |
0 | 35/181 (19.3%) * |
* including mutations on position 138. NRTI: Nucleoside Reverse Transcriptase Inhibitors; NNRTI: Non-nucleoside Reverse Transcriptase Inhibitors; PI: Protease Inhibitors.